

PharmLabs San Diego Certificate of Analysis

Sample **FVKD-3.5G-Premium-Hella Jelly**

Delta9 THC	ND	THCa	19.52%	Total THC (THCa * 0.877 + THC)	17.12%	Delta8 THC	63.02%
------------	----	------	--------	--------------------------------	--------	------------	--------



Sample ID	SD260626-026 (141887)	Matrix	Concentrate
Tested for	FVKD		
Cultivator/Manufacturer/Microbusiness License	1793	Address	325 E 9th Street Unit #10, Charlotte, NC 28202
Received	Jun 26, 2026	Name	Fortis Enterprises, Inc
Analyses executed	CANX, D9C, PRY	Reported	Jul 10, 2026
		Unit Mass (g)	3.5

Summary D9C: The total **Δ9-THC** content in this sample is 0.00%. For the most accurate **Δ9-THC** concentration, refer to the GC MS/MS section of this COA. This sample was tested using HPLC and GC MS/MS. HPLC analysis can yield inconsistent results for **Δ8-THC** and **Δ9-THC** due to isomer interference: GC MS/MS was employed to avoid this issue.

D9C - D9 Confirmation

Analyzed Jun 30, 2026 | Instrument GC MS/MS | Method SOP-041 D9C
The expanded Uncertainty of the D9 Confirmation analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppb	LOQ ppb	Result %	Result mg/g	Result mg/Unit
Δ9-Tetrahydrocannabinol (Δ9-THC)	1.462	4.432	0.00	0.00	0.00

CANx - Cannabinoids

Analyzed Jun 25, 2026 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabinavarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabidiaricin (CBDO)	0.006	0.02	ND	ND	ND
Abnormal Cannabidiaricin (a-CBDO)	0.013	0.038	ND	ND	ND
(±)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	0.07	0.69	2.42
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND
Tetrahydrocannabinavarin (THCV)	0.049	0.162	0.09	0.93	3.26
Δ8-tetrahydrocannabinavarin (Δ8-THCV)	0.021	0.064	0.57	5.73	20.06
Cannabidihexol (CBDH)	0.014	0.042	ND	ND	ND
Tetrahydrocannabinutol (Δ9-THCB)	0.01	0.029	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	0.54	5.35	18.72
Cannabidiaphoral (CBDP)	0.016	0.049	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	D9C	D9C	D9C
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	63.02	630.15	2205.52
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	19.52	195.17	683.10
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.02	0.061	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND
Δ9-Tetrahydrocannabiphoral (Δ9-THCP)	0.017	0.8	ND	ND	ND
Δ8-Tetrahydrocannabiphoral (Δ8-THCP)	0.041	0.8	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	0.24	2.40	8.40
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			17.12	171.16	599.07
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			80.13	801.31	2804.60
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			0.06	0.61	2.12
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND
Total Cannabinoids Analyzed			81.63	816.33	2857.15

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
cLOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DEA license: **RP0611043**
ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
Fri, 10 Jul 2026 08:28:02 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.